nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—schizophrenia—Dimenhydrinate—atopic dermatitis	0.26	0.569	CpDpCtD
Loxapine—schizophrenia—Diphenhydramine—atopic dermatitis	0.197	0.431	CpDpCtD
Loxapine—Azatadine—Loratadine—atopic dermatitis	0.159	0.644	CrCrCtD
Loxapine—Cyclizine—Dimenhydrinate—atopic dermatitis	0.0595	0.241	CrCrCtD
Loxapine—CHRM2—Dimenhydrinate—atopic dermatitis	0.0445	0.304	CbGbCtD
Loxapine—HRH1—Dimenhydrinate—atopic dermatitis	0.0407	0.277	CbGbCtD
Loxapine—Cyclizine—Diphenhydramine—atopic dermatitis	0.0283	0.115	CrCrCtD
Loxapine—CHRM2—Diphenhydramine—atopic dermatitis	0.0217	0.148	CbGbCtD
Loxapine—HRH1—Loratadine—atopic dermatitis	0.0199	0.135	CbGbCtD
Loxapine—HRH1—Diphenhydramine—atopic dermatitis	0.0199	0.135	CbGbCtD
Loxapine—DRD5—eyelid—atopic dermatitis	0.00638	0.338	CbGeAlD
Loxapine—CHRM5—skin epidermis—atopic dermatitis	0.00179	0.0949	CbGeAlD
Loxapine—HTR5A—head—atopic dermatitis	0.00124	0.0656	CbGeAlD
Loxapine—HRH2—skin of body—atopic dermatitis	0.00058	0.0308	CbGeAlD
Loxapine—CHRM5—skin of body—atopic dermatitis	0.000554	0.0294	CbGeAlD
Loxapine—HTR1E—head—atopic dermatitis	0.000527	0.028	CbGeAlD
Loxapine—CHRM4—head—atopic dermatitis	0.000462	0.0245	CbGeAlD
Loxapine—HTR7—neck—atopic dermatitis	0.000456	0.0242	CbGeAlD
Loxapine—DRD3—head—atopic dermatitis	0.00043	0.0228	CbGeAlD
Loxapine—HTR6—head—atopic dermatitis	0.000414	0.022	CbGeAlD
Loxapine—DRD5—head—atopic dermatitis	0.000403	0.0214	CbGeAlD
Loxapine—HRH2—head—atopic dermatitis	0.000378	0.0201	CbGeAlD
Loxapine—CHRM5—head—atopic dermatitis	0.000361	0.0192	CbGeAlD
Loxapine—ADRA1B—head—atopic dermatitis	0.00033	0.0175	CbGeAlD
Loxapine—DRD1—head—atopic dermatitis	0.000308	0.0163	CbGeAlD
Loxapine—HTR3A—head—atopic dermatitis	0.000297	0.0158	CbGeAlD
Loxapine—HTR2A—neck—atopic dermatitis	0.000284	0.0151	CbGeAlD
Loxapine—HTR1B—head—atopic dermatitis	0.000249	0.0132	CbGeAlD
Loxapine—CHRM2—head—atopic dermatitis	0.000248	0.0132	CbGeAlD
Loxapine—SLC6A3—head—atopic dermatitis	0.000247	0.0131	CbGeAlD
Loxapine—HTR1D—head—atopic dermatitis	0.000242	0.0128	CbGeAlD
Loxapine—HTR2C—head—atopic dermatitis	0.000239	0.0127	CbGeAlD
Loxapine—ADRB1—head—atopic dermatitis	0.000235	0.0125	CbGeAlD
Loxapine—SLC6A4—head—atopic dermatitis	0.000227	0.012	CbGeAlD
Loxapine—CHRM1—head—atopic dermatitis	0.000226	0.012	CbGeAlD
Loxapine—CHRM3—head—atopic dermatitis	0.000202	0.0107	CbGeAlD
Loxapine—HTR1A—head—atopic dermatitis	0.000201	0.0107	CbGeAlD
Loxapine—SLC6A2—head—atopic dermatitis	0.0002	0.0106	CbGeAlD
Loxapine—HTR7—head—atopic dermatitis	0.000192	0.0102	CbGeAlD
Loxapine—ADRA1A—head—atopic dermatitis	0.000186	0.00985	CbGeAlD
Loxapine—DRD2—head—atopic dermatitis	0.000182	0.00965	CbGeAlD
Loxapine—ADRA2C—head—atopic dermatitis	0.000177	0.00938	CbGeAlD
Loxapine—HRH1—head—atopic dermatitis	0.000144	0.00762	CbGeAlD
Loxapine—Headache—Diphenhydramine—atopic dermatitis	0.000142	0.00191	CcSEcCtD
Loxapine—ADRA2A—head—atopic dermatitis	0.000141	0.00749	CbGeAlD
Loxapine—Muscle spasms—Tacrolimus—atopic dermatitis	0.000141	0.00189	CcSEcCtD
Loxapine—Vomiting—Pimecrolimus—atopic dermatitis	0.00014	0.00188	CcSEcCtD
Loxapine—Psychotic disorder—Methylprednisolone—atopic dermatitis	0.000139	0.00187	CcSEcCtD
Loxapine—Rash—Pimecrolimus—atopic dermatitis	0.000138	0.00186	CcSEcCtD
Loxapine—Dermatitis—Pimecrolimus—atopic dermatitis	0.000138	0.00186	CcSEcCtD
Loxapine—Vision blurred—Tacrolimus—atopic dermatitis	0.000138	0.00186	CcSEcCtD
Loxapine—Headache—Pimecrolimus—atopic dermatitis	0.000138	0.00185	CcSEcCtD
Loxapine—Tremor—Tacrolimus—atopic dermatitis	0.000137	0.00185	CcSEcCtD
Loxapine—Gastrointestinal disorder—Fluocinolone Acetonide—atopic dermatitis	0.000136	0.00183	CcSEcCtD
Loxapine—Nausea—Diphenhydramine—atopic dermatitis	0.000135	0.00181	CcSEcCtD
Loxapine—Nausea—Dimenhydrinate—atopic dermatitis	0.000135	0.00181	CcSEcCtD
Loxapine—Paraesthesia—Mometasone—atopic dermatitis	0.000135	0.00181	CcSEcCtD
Loxapine—Agitation—Tacrolimus—atopic dermatitis	0.000135	0.00181	CcSEcCtD
Loxapine—Dyspnoea—Mometasone—atopic dermatitis	0.000134	0.0018	CcSEcCtD
Loxapine—Syncope—Tacrolimus—atopic dermatitis	0.000131	0.00177	CcSEcCtD
Loxapine—Leukopenia—Tacrolimus—atopic dermatitis	0.000131	0.00176	CcSEcCtD
Loxapine—Nausea—Pimecrolimus—atopic dermatitis	0.00013	0.00175	CcSEcCtD
Loxapine—Fatigue—Mometasone—atopic dermatitis	0.000129	0.00174	CcSEcCtD
Loxapine—Loss of consciousness—Tacrolimus—atopic dermatitis	0.000129	0.00173	CcSEcCtD
Loxapine—Cough—Tacrolimus—atopic dermatitis	0.000128	0.00172	CcSEcCtD
Loxapine—Convulsion—Tacrolimus—atopic dermatitis	0.000127	0.00171	CcSEcCtD
Loxapine—Psychotic disorder—Betamethasone—atopic dermatitis	0.000127	0.0017	CcSEcCtD
Loxapine—Psychotic disorder—Dexamethasone—atopic dermatitis	0.000127	0.0017	CcSEcCtD
Loxapine—Hypertension—Tacrolimus—atopic dermatitis	0.000126	0.0017	CcSEcCtD
Loxapine—Asthenia—Loratadine—atopic dermatitis	0.000126	0.00169	CcSEcCtD
Loxapine—Chest pain—Tacrolimus—atopic dermatitis	0.000125	0.00168	CcSEcCtD
Loxapine—Weight increased—Prednisolone—atopic dermatitis	0.000122	0.00164	CcSEcCtD
Loxapine—Dry mouth—Tacrolimus—atopic dermatitis	0.000122	0.00164	CcSEcCtD
Loxapine—Bronchospasm—Methylprednisolone—atopic dermatitis	0.000121	0.00163	CcSEcCtD
Loxapine—Confusional state—Tacrolimus—atopic dermatitis	0.00012	0.00162	CcSEcCtD
Loxapine—HTR2A—head—atopic dermatitis	0.00012	0.00637	CbGeAlD
Loxapine—Oedema—Tacrolimus—atopic dermatitis	0.000119	0.00161	CcSEcCtD
Loxapine—Weight increased—Hydrocortisone—atopic dermatitis	0.000119	0.0016	CcSEcCtD
Loxapine—Weight decreased—Hydrocortisone—atopic dermatitis	0.000119	0.0016	CcSEcCtD
Loxapine—Shock—Tacrolimus—atopic dermatitis	0.000118	0.00158	CcSEcCtD
Loxapine—Nervous system disorder—Tacrolimus—atopic dermatitis	0.000117	0.00158	CcSEcCtD
Loxapine—Thrombocytopenia—Tacrolimus—atopic dermatitis	0.000117	0.00157	CcSEcCtD
Loxapine—Tachycardia—Tacrolimus—atopic dermatitis	0.000117	0.00157	CcSEcCtD
Loxapine—Hypersensitivity—Fluocinolone Acetonide—atopic dermatitis	0.000116	0.00156	CcSEcCtD
Loxapine—Dizziness—Loratadine—atopic dermatitis	0.000116	0.00156	CcSEcCtD
Loxapine—Weight increased—Triamcinolone—atopic dermatitis	0.000112	0.00151	CcSEcCtD
Loxapine—Weight increased—Methylprednisolone—atopic dermatitis	0.000112	0.00151	CcSEcCtD
Loxapine—Hypotension—Tacrolimus—atopic dermatitis	0.000112	0.0015	CcSEcCtD
Loxapine—Pruritus—Fluocinolone Acetonide—atopic dermatitis	0.000111	0.0015	CcSEcCtD
Loxapine—Vomiting—Loratadine—atopic dermatitis	0.000111	0.0015	CcSEcCtD
Loxapine—Rash—Loratadine—atopic dermatitis	0.00011	0.00148	CcSEcCtD
Loxapine—Psychotic disorder—Prednisone—atopic dermatitis	0.00011	0.00148	CcSEcCtD
Loxapine—Dermatitis—Loratadine—atopic dermatitis	0.00011	0.00148	CcSEcCtD
Loxapine—Headache—Loratadine—atopic dermatitis	0.00011	0.00147	CcSEcCtD
Loxapine—Insomnia—Tacrolimus—atopic dermatitis	0.000108	0.00145	CcSEcCtD
Loxapine—Asthenia—Mometasone—atopic dermatitis	0.000108	0.00145	CcSEcCtD
Loxapine—Paraesthesia—Tacrolimus—atopic dermatitis	0.000107	0.00144	CcSEcCtD
Loxapine—Dyspnoea—Tacrolimus—atopic dermatitis	0.000107	0.00143	CcSEcCtD
Loxapine—Somnolence—Tacrolimus—atopic dermatitis	0.000106	0.00143	CcSEcCtD
Loxapine—Pruritus—Mometasone—atopic dermatitis	0.000106	0.00143	CcSEcCtD
Loxapine—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000104	0.0014	CcSEcCtD
Loxapine—Nausea—Loratadine—atopic dermatitis	0.000104	0.0014	CcSEcCtD
Loxapine—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000103	0.00139	CcSEcCtD
Loxapine—Fatigue—Tacrolimus—atopic dermatitis	0.000103	0.00139	CcSEcCtD
Loxapine—Constipation—Tacrolimus—atopic dermatitis	0.000102	0.00137	CcSEcCtD
Loxapine—Weight increased—Dexamethasone—atopic dermatitis	0.000102	0.00137	CcSEcCtD
Loxapine—Weight increased—Betamethasone—atopic dermatitis	0.000102	0.00137	CcSEcCtD
Loxapine—Weight decreased—Dexamethasone—atopic dermatitis	0.000101	0.00136	CcSEcCtD
Loxapine—Weight decreased—Betamethasone—atopic dermatitis	0.000101	0.00136	CcSEcCtD
Loxapine—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.0001	0.00134	CcSEcCtD
Loxapine—Rash—Fluocinolone Acetonide—atopic dermatitis	9.91e-05	0.00133	CcSEcCtD
Loxapine—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	9.9e-05	0.00133	CcSEcCtD
Loxapine—Headache—Fluocinolone Acetonide—atopic dermatitis	9.85e-05	0.00132	CcSEcCtD
Loxapine—Feeling abnormal—Tacrolimus—atopic dermatitis	9.85e-05	0.00132	CcSEcCtD
Loxapine—Vomiting—Mometasone—atopic dermatitis	9.55e-05	0.00128	CcSEcCtD
Loxapine—Rash—Mometasone—atopic dermatitis	9.47e-05	0.00127	CcSEcCtD
Loxapine—Dermatitis—Mometasone—atopic dermatitis	9.46e-05	0.00127	CcSEcCtD
Loxapine—Headache—Mometasone—atopic dermatitis	9.41e-05	0.00127	CcSEcCtD
Loxapine—Nausea—Fluocinolone Acetonide—atopic dermatitis	9.34e-05	0.00126	CcSEcCtD
Loxapine—Angiopathy—Methylprednisolone—atopic dermatitis	8.94e-05	0.0012	CcSEcCtD
Loxapine—Nausea—Mometasone—atopic dermatitis	8.92e-05	0.0012	CcSEcCtD
Loxapine—Mediastinal disorder—Methylprednisolone—atopic dermatitis	8.88e-05	0.0012	CcSEcCtD
Loxapine—Weight increased—Prednisone—atopic dermatitis	8.88e-05	0.00119	CcSEcCtD
Loxapine—Weight decreased—Prednisone—atopic dermatitis	8.82e-05	0.00119	CcSEcCtD
Loxapine—Vision blurred—Prednisolone—atopic dermatitis	8.81e-05	0.00119	CcSEcCtD
Loxapine—Hypersensitivity—Tacrolimus—atopic dermatitis	8.8e-05	0.00118	CcSEcCtD
Loxapine—Asthenia—Tacrolimus—atopic dermatitis	8.57e-05	0.00115	CcSEcCtD
Loxapine—Pruritus—Tacrolimus—atopic dermatitis	8.45e-05	0.00114	CcSEcCtD
Loxapine—Dysgeusia—Triamcinolone—atopic dermatitis	8.42e-05	0.00113	CcSEcCtD
Loxapine—Syncope—Prednisolone—atopic dermatitis	8.39e-05	0.00113	CcSEcCtD
Loxapine—Loss of consciousness—Prednisolone—atopic dermatitis	8.22e-05	0.00111	CcSEcCtD
Loxapine—Syncope—Hydrocortisone—atopic dermatitis	8.19e-05	0.0011	CcSEcCtD
Loxapine—Angiopathy—Dexamethasone—atopic dermatitis	8.13e-05	0.00109	CcSEcCtD
Loxapine—Angiopathy—Betamethasone—atopic dermatitis	8.13e-05	0.00109	CcSEcCtD
Loxapine—Convulsion—Prednisolone—atopic dermatitis	8.1e-05	0.00109	CcSEcCtD
Loxapine—Hypertension—Prednisolone—atopic dermatitis	8.07e-05	0.00109	CcSEcCtD
Loxapine—Loss of consciousness—Hydrocortisone—atopic dermatitis	8.03e-05	0.00108	CcSEcCtD
Loxapine—Alopecia—Betamethasone—atopic dermatitis	7.92e-05	0.00107	CcSEcCtD
Loxapine—Alopecia—Dexamethasone—atopic dermatitis	7.92e-05	0.00107	CcSEcCtD
Loxapine—Convulsion—Hydrocortisone—atopic dermatitis	7.91e-05	0.00106	CcSEcCtD
Loxapine—Dizziness—Tacrolimus—atopic dermatitis	7.9e-05	0.00106	CcSEcCtD
Loxapine—Hypertension—Hydrocortisone—atopic dermatitis	7.89e-05	0.00106	CcSEcCtD
Loxapine—Syncope—Triamcinolone—atopic dermatitis	7.71e-05	0.00104	CcSEcCtD
Loxapine—Syncope—Methylprednisolone—atopic dermatitis	7.7e-05	0.00104	CcSEcCtD
Loxapine—Oedema—Prednisolone—atopic dermatitis	7.63e-05	0.00103	CcSEcCtD
Loxapine—Vomiting—Tacrolimus—atopic dermatitis	7.6e-05	0.00102	CcSEcCtD
Loxapine—Loss of consciousness—Triamcinolone—atopic dermatitis	7.56e-05	0.00102	CcSEcCtD
Loxapine—Loss of consciousness—Methylprednisolone—atopic dermatitis	7.54e-05	0.00101	CcSEcCtD
Loxapine—Rash—Tacrolimus—atopic dermatitis	7.53e-05	0.00101	CcSEcCtD
Loxapine—Dermatitis—Tacrolimus—atopic dermatitis	7.53e-05	0.00101	CcSEcCtD
Loxapine—Shock—Prednisolone—atopic dermatitis	7.51e-05	0.00101	CcSEcCtD
Loxapine—Cough—Triamcinolone—atopic dermatitis	7.5e-05	0.00101	CcSEcCtD
Loxapine—Headache—Tacrolimus—atopic dermatitis	7.49e-05	0.00101	CcSEcCtD
Loxapine—Oedema—Hydrocortisone—atopic dermatitis	7.45e-05	0.001	CcSEcCtD
Loxapine—Convulsion—Triamcinolone—atopic dermatitis	7.45e-05	0.001	CcSEcCtD
Loxapine—Tachycardia—Prednisolone—atopic dermatitis	7.45e-05	0.001	CcSEcCtD
Loxapine—Convulsion—Methylprednisolone—atopic dermatitis	7.43e-05	0.001	CcSEcCtD
Loxapine—Hypertension—Triamcinolone—atopic dermatitis	7.43e-05	0.000999	CcSEcCtD
Loxapine—Hypertension—Methylprednisolone—atopic dermatitis	7.41e-05	0.000997	CcSEcCtD
Loxapine—Shock—Hydrocortisone—atopic dermatitis	7.33e-05	0.000986	CcSEcCtD
Loxapine—Nervous system disorder—Hydrocortisone—atopic dermatitis	7.31e-05	0.000983	CcSEcCtD
Loxapine—Tachycardia—Hydrocortisone—atopic dermatitis	7.28e-05	0.000979	CcSEcCtD
Loxapine—Dry mouth—Triamcinolone—atopic dermatitis	7.16e-05	0.000963	CcSEcCtD
Loxapine—Nausea—Tacrolimus—atopic dermatitis	7.1e-05	0.000955	CcSEcCtD
Loxapine—Angiopathy—Prednisone—atopic dermatitis	7.08e-05	0.000953	CcSEcCtD
Loxapine—Confusional state—Methylprednisolone—atopic dermatitis	7.06e-05	0.00095	CcSEcCtD
Loxapine—Oedema—Triamcinolone—atopic dermatitis	7.02e-05	0.000944	CcSEcCtD
Loxapine—Syncope—Dexamethasone—atopic dermatitis	7e-05	0.000941	CcSEcCtD
Loxapine—Syncope—Betamethasone—atopic dermatitis	7e-05	0.000941	CcSEcCtD
Loxapine—Hypotension—Hydrocortisone—atopic dermatitis	6.97e-05	0.000937	CcSEcCtD
Loxapine—Shock—Triamcinolone—atopic dermatitis	6.91e-05	0.000929	CcSEcCtD
Loxapine—Insomnia—Prednisolone—atopic dermatitis	6.9e-05	0.000929	CcSEcCtD
Loxapine—Alopecia—Prednisone—atopic dermatitis	6.9e-05	0.000928	CcSEcCtD
Loxapine—Shock—Methylprednisolone—atopic dermatitis	6.89e-05	0.000927	CcSEcCtD
Loxapine—Nervous system disorder—Methylprednisolone—atopic dermatitis	6.87e-05	0.000924	CcSEcCtD
Loxapine—Loss of consciousness—Betamethasone—atopic dermatitis	6.86e-05	0.000923	CcSEcCtD
Loxapine—Loss of consciousness—Dexamethasone—atopic dermatitis	6.86e-05	0.000923	CcSEcCtD
Loxapine—Paraesthesia—Prednisolone—atopic dermatitis	6.85e-05	0.000922	CcSEcCtD
Loxapine—Tachycardia—Triamcinolone—atopic dermatitis	6.85e-05	0.000921	CcSEcCtD
Loxapine—Tachycardia—Methylprednisolone—atopic dermatitis	6.83e-05	0.000919	CcSEcCtD
Loxapine—Convulsion—Dexamethasone—atopic dermatitis	6.76e-05	0.000909	CcSEcCtD
Loxapine—Convulsion—Betamethasone—atopic dermatitis	6.76e-05	0.000909	CcSEcCtD
Loxapine—Insomnia—Hydrocortisone—atopic dermatitis	6.74e-05	0.000907	CcSEcCtD
Loxapine—Hypertension—Dexamethasone—atopic dermatitis	6.74e-05	0.000906	CcSEcCtD
Loxapine—Hypertension—Betamethasone—atopic dermatitis	6.74e-05	0.000906	CcSEcCtD
Loxapine—Paraesthesia—Hydrocortisone—atopic dermatitis	6.69e-05	0.0009	CcSEcCtD
Loxapine—Hypotension—Methylprednisolone—atopic dermatitis	6.54e-05	0.00088	CcSEcCtD
Loxapine—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	6.44e-05	0.000866	CcSEcCtD
Loxapine—Fatigue—Hydrocortisone—atopic dermatitis	6.43e-05	0.000864	CcSEcCtD
Loxapine—Vision blurred—Prednisone—atopic dermatitis	6.4e-05	0.000861	CcSEcCtD
Loxapine—Oedema—Betamethasone—atopic dermatitis	6.37e-05	0.000857	CcSEcCtD
Loxapine—Oedema—Dexamethasone—atopic dermatitis	6.37e-05	0.000857	CcSEcCtD
Loxapine—Insomnia—Triamcinolone—atopic dermatitis	6.35e-05	0.000854	CcSEcCtD
Loxapine—Insomnia—Methylprednisolone—atopic dermatitis	6.33e-05	0.000852	CcSEcCtD
Loxapine—Paraesthesia—Triamcinolone—atopic dermatitis	6.3e-05	0.000848	CcSEcCtD
Loxapine—Feeling abnormal—Prednisolone—atopic dermatitis	6.29e-05	0.000846	CcSEcCtD
Loxapine—Paraesthesia—Methylprednisolone—atopic dermatitis	6.29e-05	0.000846	CcSEcCtD
Loxapine—Shock—Dexamethasone—atopic dermatitis	6.27e-05	0.000843	CcSEcCtD
Loxapine—Shock—Betamethasone—atopic dermatitis	6.27e-05	0.000843	CcSEcCtD
Loxapine—Dyspnoea—Triamcinolone—atopic dermatitis	6.26e-05	0.000842	CcSEcCtD
Loxapine—Nervous system disorder—Dexamethasone—atopic dermatitis	6.25e-05	0.00084	CcSEcCtD
Loxapine—Nervous system disorder—Betamethasone—atopic dermatitis	6.25e-05	0.00084	CcSEcCtD
Loxapine—Agitation—Prednisone—atopic dermatitis	6.25e-05	0.00084	CcSEcCtD
Loxapine—Thrombocytopenia—Betamethasone—atopic dermatitis	6.24e-05	0.000839	CcSEcCtD
Loxapine—Thrombocytopenia—Dexamethasone—atopic dermatitis	6.24e-05	0.000839	CcSEcCtD
Loxapine—Tachycardia—Betamethasone—atopic dermatitis	6.22e-05	0.000836	CcSEcCtD
Loxapine—Tachycardia—Dexamethasone—atopic dermatitis	6.22e-05	0.000836	CcSEcCtD
Loxapine—Feeling abnormal—Hydrocortisone—atopic dermatitis	6.14e-05	0.000826	CcSEcCtD
Loxapine—Syncope—Prednisone—atopic dermatitis	6.09e-05	0.00082	CcSEcCtD
Loxapine—Fatigue—Triamcinolone—atopic dermatitis	6.05e-05	0.000814	CcSEcCtD
Loxapine—Fatigue—Methylprednisolone—atopic dermatitis	6.04e-05	0.000812	CcSEcCtD
Loxapine—Loss of consciousness—Prednisone—atopic dermatitis	5.97e-05	0.000803	CcSEcCtD
Loxapine—Hypotension—Betamethasone—atopic dermatitis	5.95e-05	0.0008	CcSEcCtD
Loxapine—Hypotension—Dexamethasone—atopic dermatitis	5.95e-05	0.0008	CcSEcCtD
Loxapine—Convulsion—Prednisone—atopic dermatitis	5.89e-05	0.000792	CcSEcCtD
Loxapine—Hypertension—Prednisone—atopic dermatitis	5.87e-05	0.000789	CcSEcCtD
Loxapine—Feeling abnormal—Triamcinolone—atopic dermatitis	5.78e-05	0.000778	CcSEcCtD
Loxapine—Feeling abnormal—Methylprednisolone—atopic dermatitis	5.77e-05	0.000776	CcSEcCtD
Loxapine—Insomnia—Betamethasone—atopic dermatitis	5.76e-05	0.000775	CcSEcCtD
Loxapine—Insomnia—Dexamethasone—atopic dermatitis	5.76e-05	0.000775	CcSEcCtD
Loxapine—Paraesthesia—Dexamethasone—atopic dermatitis	5.72e-05	0.000769	CcSEcCtD
Loxapine—Paraesthesia—Betamethasone—atopic dermatitis	5.72e-05	0.000769	CcSEcCtD
Loxapine—Hypersensitivity—Prednisolone—atopic dermatitis	5.62e-05	0.000756	CcSEcCtD
Loxapine—Oedema—Prednisone—atopic dermatitis	5.55e-05	0.000746	CcSEcCtD
Loxapine—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	5.5e-05	0.00074	CcSEcCtD
Loxapine—Gastrointestinal disorder—Betamethasone—atopic dermatitis	5.5e-05	0.00074	CcSEcCtD
Loxapine—Hypersensitivity—Hydrocortisone—atopic dermatitis	5.49e-05	0.000739	CcSEcCtD
Loxapine—Fatigue—Betamethasone—atopic dermatitis	5.49e-05	0.000739	CcSEcCtD
Loxapine—Fatigue—Dexamethasone—atopic dermatitis	5.49e-05	0.000739	CcSEcCtD
Loxapine—Shock—Prednisone—atopic dermatitis	5.46e-05	0.000734	CcSEcCtD
Loxapine—Nervous system disorder—Prednisone—atopic dermatitis	5.44e-05	0.000732	CcSEcCtD
Loxapine—Tachycardia—Prednisone—atopic dermatitis	5.41e-05	0.000728	CcSEcCtD
Loxapine—Asthenia—Hydrocortisone—atopic dermatitis	5.35e-05	0.000719	CcSEcCtD
Loxapine—Pruritus—Hydrocortisone—atopic dermatitis	5.27e-05	0.000709	CcSEcCtD
Loxapine—Feeling abnormal—Dexamethasone—atopic dermatitis	5.25e-05	0.000706	CcSEcCtD
Loxapine—Feeling abnormal—Betamethasone—atopic dermatitis	5.25e-05	0.000706	CcSEcCtD
Loxapine—Hypersensitivity—Triamcinolone—atopic dermatitis	5.17e-05	0.000696	CcSEcCtD
Loxapine—Hypersensitivity—Methylprednisolone—atopic dermatitis	5.16e-05	0.000694	CcSEcCtD
Loxapine—Dizziness—Prednisolone—atopic dermatitis	5.05e-05	0.000679	CcSEcCtD
Loxapine—Asthenia—Triamcinolone—atopic dermatitis	5.04e-05	0.000677	CcSEcCtD
Loxapine—Asthenia—Methylprednisolone—atopic dermatitis	5.02e-05	0.000676	CcSEcCtD
Loxapine—Insomnia—Prednisone—atopic dermatitis	5.02e-05	0.000675	CcSEcCtD
Loxapine—Paraesthesia—Prednisone—atopic dermatitis	4.98e-05	0.00067	CcSEcCtD
Loxapine—Pruritus—Triamcinolone—atopic dermatitis	4.97e-05	0.000668	CcSEcCtD
Loxapine—Pruritus—Methylprednisolone—atopic dermatitis	4.95e-05	0.000666	CcSEcCtD
Loxapine—Dizziness—Hydrocortisone—atopic dermatitis	4.93e-05	0.000663	CcSEcCtD
Loxapine—Rash—Prednisolone—atopic dermatitis	4.81e-05	0.000647	CcSEcCtD
Loxapine—Dermatitis—Prednisolone—atopic dermatitis	4.81e-05	0.000647	CcSEcCtD
Loxapine—Fatigue—Prednisone—atopic dermatitis	4.78e-05	0.000643	CcSEcCtD
Loxapine—Headache—Prednisolone—atopic dermatitis	4.78e-05	0.000643	CcSEcCtD
Loxapine—Constipation—Prednisone—atopic dermatitis	4.74e-05	0.000638	CcSEcCtD
Loxapine—Vomiting—Hydrocortisone—atopic dermatitis	4.74e-05	0.000638	CcSEcCtD
Loxapine—Rash—Hydrocortisone—atopic dermatitis	4.7e-05	0.000632	CcSEcCtD
Loxapine—Dermatitis—Hydrocortisone—atopic dermatitis	4.7e-05	0.000632	CcSEcCtD
Loxapine—Headache—Hydrocortisone—atopic dermatitis	4.67e-05	0.000628	CcSEcCtD
Loxapine—Dizziness—Triamcinolone—atopic dermatitis	4.64e-05	0.000624	CcSEcCtD
Loxapine—Dizziness—Methylprednisolone—atopic dermatitis	4.63e-05	0.000623	CcSEcCtD
Loxapine—Feeling abnormal—Prednisone—atopic dermatitis	4.57e-05	0.000615	CcSEcCtD
Loxapine—Asthenia—Betamethasone—atopic dermatitis	4.57e-05	0.000615	CcSEcCtD
Loxapine—Asthenia—Dexamethasone—atopic dermatitis	4.57e-05	0.000615	CcSEcCtD
Loxapine—Nausea—Prednisolone—atopic dermatitis	4.53e-05	0.00061	CcSEcCtD
Loxapine—Pruritus—Dexamethasone—atopic dermatitis	4.51e-05	0.000606	CcSEcCtD
Loxapine—Pruritus—Betamethasone—atopic dermatitis	4.51e-05	0.000606	CcSEcCtD
Loxapine—Vomiting—Triamcinolone—atopic dermatitis	4.46e-05	0.0006	CcSEcCtD
Loxapine—Vomiting—Methylprednisolone—atopic dermatitis	4.45e-05	0.000599	CcSEcCtD
Loxapine—Nausea—Hydrocortisone—atopic dermatitis	4.43e-05	0.000596	CcSEcCtD
Loxapine—Rash—Triamcinolone—atopic dermatitis	4.43e-05	0.000595	CcSEcCtD
Loxapine—Dermatitis—Triamcinolone—atopic dermatitis	4.42e-05	0.000595	CcSEcCtD
Loxapine—Rash—Methylprednisolone—atopic dermatitis	4.42e-05	0.000594	CcSEcCtD
Loxapine—Dermatitis—Methylprednisolone—atopic dermatitis	4.41e-05	0.000593	CcSEcCtD
Loxapine—Headache—Triamcinolone—atopic dermatitis	4.4e-05	0.000591	CcSEcCtD
Loxapine—Headache—Methylprednisolone—atopic dermatitis	4.39e-05	0.00059	CcSEcCtD
Loxapine—Dizziness—Dexamethasone—atopic dermatitis	4.21e-05	0.000566	CcSEcCtD
Loxapine—Dizziness—Betamethasone—atopic dermatitis	4.21e-05	0.000566	CcSEcCtD
Loxapine—Nausea—Triamcinolone—atopic dermatitis	4.17e-05	0.000561	CcSEcCtD
Loxapine—Nausea—Methylprednisolone—atopic dermatitis	4.16e-05	0.00056	CcSEcCtD
Loxapine—Hypersensitivity—Prednisone—atopic dermatitis	4.09e-05	0.00055	CcSEcCtD
Loxapine—Vomiting—Betamethasone—atopic dermatitis	4.05e-05	0.000545	CcSEcCtD
Loxapine—Vomiting—Dexamethasone—atopic dermatitis	4.05e-05	0.000545	CcSEcCtD
Loxapine—Rash—Dexamethasone—atopic dermatitis	4.02e-05	0.00054	CcSEcCtD
Loxapine—Rash—Betamethasone—atopic dermatitis	4.02e-05	0.00054	CcSEcCtD
Loxapine—Dermatitis—Betamethasone—atopic dermatitis	4.01e-05	0.00054	CcSEcCtD
Loxapine—Dermatitis—Dexamethasone—atopic dermatitis	4.01e-05	0.00054	CcSEcCtD
Loxapine—Headache—Betamethasone—atopic dermatitis	3.99e-05	0.000537	CcSEcCtD
Loxapine—Headache—Dexamethasone—atopic dermatitis	3.99e-05	0.000537	CcSEcCtD
Loxapine—Asthenia—Prednisone—atopic dermatitis	3.98e-05	0.000535	CcSEcCtD
Loxapine—Pruritus—Prednisone—atopic dermatitis	3.92e-05	0.000528	CcSEcCtD
Loxapine—Nausea—Betamethasone—atopic dermatitis	3.78e-05	0.000509	CcSEcCtD
Loxapine—Nausea—Dexamethasone—atopic dermatitis	3.78e-05	0.000509	CcSEcCtD
Loxapine—Dizziness—Prednisone—atopic dermatitis	3.67e-05	0.000493	CcSEcCtD
Loxapine—Vomiting—Prednisone—atopic dermatitis	3.53e-05	0.000474	CcSEcCtD
Loxapine—Rash—Prednisone—atopic dermatitis	3.5e-05	0.00047	CcSEcCtD
Loxapine—Dermatitis—Prednisone—atopic dermatitis	3.49e-05	0.00047	CcSEcCtD
Loxapine—Headache—Prednisone—atopic dermatitis	3.47e-05	0.000467	CcSEcCtD
Loxapine—Nausea—Prednisone—atopic dermatitis	3.29e-05	0.000443	CcSEcCtD
Loxapine—HTR2C—GPCR downstream signaling—CXCL8—atopic dermatitis	4.52e-06	8.03e-05	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—IL2—atopic dermatitis	4.49e-06	7.99e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL10—atopic dermatitis	4.49e-06	7.98e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—NFKBIA—atopic dermatitis	4.48e-06	7.97e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL10—atopic dermatitis	4.48e-06	7.96e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCL5—atopic dermatitis	4.47e-06	7.95e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PPARA—atopic dermatitis	4.47e-06	7.94e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL10—atopic dermatitis	4.46e-06	7.93e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL10—atopic dermatitis	4.45e-06	7.91e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCL5—atopic dermatitis	4.45e-06	7.91e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—NFKBIA—atopic dermatitis	4.41e-06	7.84e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL10—atopic dermatitis	4.41e-06	7.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL10—atopic dermatitis	4.39e-06	7.81e-05	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—CXCL8—atopic dermatitis	4.39e-06	7.81e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—NFKBIA—atopic dermatitis	4.35e-06	7.74e-05	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—IL2—atopic dermatitis	4.34e-06	7.71e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NGF—atopic dermatitis	4.33e-06	7.7e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCL5—atopic dermatitis	4.33e-06	7.69e-05	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—CXCL8—atopic dermatitis	4.32e-06	7.69e-05	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—IL2—atopic dermatitis	4.32e-06	7.67e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—CXCL8—atopic dermatitis	4.31e-06	7.66e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—CXCL8—atopic dermatitis	4.29e-06	7.63e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NGF—atopic dermatitis	4.29e-06	7.63e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—CXCL8—atopic dermatitis	4.27e-06	7.59e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—CXCL8—atopic dermatitis	4.26e-06	7.58e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCL5—atopic dermatitis	4.26e-06	7.57e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—MAPK8—atopic dermatitis	4.24e-06	7.53e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CCR5—atopic dermatitis	4.21e-06	7.49e-05	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—IL2—atopic dermatitis	4.2e-06	7.46e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CCR5—atopic dermatitis	4.17e-06	7.42e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—NFKBIA—atopic dermatitis	4.17e-06	7.41e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NGF—atopic dermatitis	4.14e-06	7.36e-05	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—IL2—atopic dermatitis	4.13e-06	7.34e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—CXCL8—atopic dermatitis	4.12e-06	7.33e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NGF—atopic dermatitis	4.12e-06	7.32e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL2—atopic dermatitis	4.12e-06	7.32e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—CXCL8—atopic dermatitis	4.1e-06	7.29e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL2—atopic dermatitis	4.1e-06	7.29e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL10—atopic dermatitis	4.08e-06	7.26e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL2—atopic dermatitis	4.08e-06	7.26e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling by GPCR—IL6—atopic dermatitis	4.08e-06	7.25e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL2—atopic dermatitis	4.07e-06	7.24e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling by GPCR—IL6—atopic dermatitis	4.05e-06	7.2e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCR5—atopic dermatitis	4.03e-06	7.16e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCR5—atopic dermatitis	4.01e-06	7.12e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NGF—atopic dermatitis	4.01e-06	7.12e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—CXCL8—atopic dermatitis	3.99e-06	7.09e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—CXCL8—atopic dermatitis	3.99e-06	7.09e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—NFKBIA—atopic dermatitis	3.97e-06	7.06e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PPARA—atopic dermatitis	3.96e-06	7.03e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NGF—atopic dermatitis	3.94e-06	7.01e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL2—atopic dermatitis	3.94e-06	7e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—CXCL8—atopic dermatitis	3.93e-06	6.98e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCL5—atopic dermatitis	3.93e-06	6.98e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—CXCL8—atopic dermatitis	3.92e-06	6.97e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL2—atopic dermatitis	3.92e-06	6.97e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NFKBIA—atopic dermatitis	3.92e-06	6.97e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—CXCL8—atopic dermatitis	3.91e-06	6.96e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—CXCL8—atopic dermatitis	3.9e-06	6.93e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCR5—atopic dermatitis	3.9e-06	6.93e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—CXCL8—atopic dermatitis	3.89e-06	6.91e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCL5—atopic dermatitis	3.86e-06	6.87e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCL5—atopic dermatitis	3.85e-06	6.85e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—CXCL8—atopic dermatitis	3.85e-06	6.85e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCL5—atopic dermatitis	3.84e-06	6.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—CXCL8—atopic dermatitis	3.84e-06	6.83e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCR5—atopic dermatitis	3.84e-06	6.82e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCL5—atopic dermatitis	3.83e-06	6.81e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL2—atopic dermatitis	3.81e-06	6.78e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—IL2—atopic dermatitis	3.81e-06	6.77e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCL5—atopic dermatitis	3.79e-06	6.74e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCL5—atopic dermatitis	3.78e-06	6.72e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—MAPK8—atopic dermatitis	3.77e-06	6.71e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL2—atopic dermatitis	3.75e-06	6.67e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—MAPK8—atopic dermatitis	3.75e-06	6.67e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—IL2—atopic dermatitis	3.75e-06	6.66e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—IL2—atopic dermatitis	3.74e-06	6.65e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—IL2—atopic dermatitis	3.73e-06	6.63e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—IL2—atopic dermatitis	3.72e-06	6.61e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—IL2—atopic dermatitis	3.68e-06	6.54e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—IL2—atopic dermatitis	3.67e-06	6.52e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NGF—atopic dermatitis	3.64e-06	6.46e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PPARA—atopic dermatitis	3.63e-06	6.45e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—CXCL8—atopic dermatitis	3.62e-06	6.43e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NGF—atopic dermatitis	3.58e-06	6.36e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NFKBIA—atopic dermatitis	3.57e-06	6.35e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NGF—atopic dermatitis	3.57e-06	6.35e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—CXCL8—atopic dermatitis	3.57e-06	6.34e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—CXCL8—atopic dermatitis	3.56e-06	6.33e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NGF—atopic dermatitis	3.56e-06	6.33e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—CXCL8—atopic dermatitis	3.55e-06	6.32e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NGF—atopic dermatitis	3.55e-06	6.3e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—CXCL8—atopic dermatitis	3.54e-06	6.3e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NFKBIA—atopic dermatitis	3.54e-06	6.29e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCR5—atopic dermatitis	3.54e-06	6.29e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—CXCL8—atopic dermatitis	3.53e-06	6.28e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL5—atopic dermatitis	3.51e-06	6.25e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NGF—atopic dermatitis	3.51e-06	6.24e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NGF—atopic dermatitis	3.5e-06	6.23e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—CXCL8—atopic dermatitis	3.5e-06	6.22e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—CXCL8—atopic dermatitis	3.49e-06	6.2e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCR5—atopic dermatitis	3.48e-06	6.19e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCR5—atopic dermatitis	3.47e-06	6.17e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCR5—atopic dermatitis	3.46e-06	6.15e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL2—atopic dermatitis	3.46e-06	6.15e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCR5—atopic dermatitis	3.45e-06	6.13e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCR5—atopic dermatitis	3.42e-06	6.07e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NFKBIA—atopic dermatitis	3.42e-06	6.07e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—IL2—atopic dermatitis	3.41e-06	6.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCR5—atopic dermatitis	3.41e-06	6.06e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL2—atopic dermatitis	3.4e-06	6.05e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NFKBIA—atopic dermatitis	3.4e-06	6.04e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL2—atopic dermatitis	3.4e-06	6.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL2—atopic dermatitis	3.39e-06	6.02e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL2—atopic dermatitis	3.38e-06	6e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL2—atopic dermatitis	3.34e-06	5.94e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL2—atopic dermatitis	3.33e-06	5.92e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NFKBIA—atopic dermatitis	3.3e-06	5.87e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CXCL8—atopic dermatitis	3.29e-06	5.85e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CXCL8—atopic dermatitis	3.29e-06	5.84e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CXCL8—atopic dermatitis	3.27e-06	5.8e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NGF—atopic dermatitis	3.25e-06	5.79e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NFKBIA—atopic dermatitis	3.25e-06	5.78e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—CXCL8—atopic dermatitis	3.24e-06	5.76e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CXCL8—atopic dermatitis	3.2e-06	5.68e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCR5—atopic dermatitis	3.17e-06	5.63e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CXCL8—atopic dermatitis	3.15e-06	5.59e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL2—atopic dermatitis	3.14e-06	5.59e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL2—atopic dermatitis	3.14e-06	5.58e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—atopic dermatitis	3.13e-06	5.56e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—atopic dermatitis	3.13e-06	5.56e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL2—atopic dermatitis	3.12e-06	5.55e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—atopic dermatitis	3.11e-06	5.52e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—atopic dermatitis	3.1e-06	5.52e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CXCL8—atopic dermatitis	3.1e-06	5.52e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL2—atopic dermatitis	3.1e-06	5.5e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL2—atopic dermatitis	3.06e-06	5.43e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—atopic dermatitis	3.04e-06	5.4e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL2—atopic dermatitis	3.01e-06	5.34e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NFKBIA—atopic dermatitis	3e-06	5.33e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—atopic dermatitis	2.99e-06	5.32e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CXCL8—atopic dermatitis	2.97e-06	5.28e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL2—atopic dermatitis	2.97e-06	5.27e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—atopic dermatitis	2.95e-06	5.25e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NFKBIA—atopic dermatitis	2.95e-06	5.24e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NFKBIA—atopic dermatitis	2.94e-06	5.23e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NFKBIA—atopic dermatitis	2.93e-06	5.22e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NFKBIA—atopic dermatitis	2.93e-06	5.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NFKBIA—atopic dermatitis	2.9e-06	5.15e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MAPK8—atopic dermatitis	2.89e-06	5.14e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MAPK8—atopic dermatitis	2.89e-06	5.14e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NFKBIA—atopic dermatitis	2.89e-06	5.14e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MAPK8—atopic dermatitis	2.87e-06	5.11e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL2—atopic dermatitis	2.84e-06	5.05e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CXCL8—atopic dermatitis	2.83e-06	5.03e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—atopic dermatitis	2.83e-06	5.02e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MAPK8—atopic dermatitis	2.81e-06	5e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CXCL8—atopic dermatitis	2.79e-06	4.97e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MAPK8—atopic dermatitis	2.77e-06	4.92e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MAPK8—atopic dermatitis	2.73e-06	4.85e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL2—atopic dermatitis	2.71e-06	4.81e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—atopic dermatitis	2.71e-06	4.81e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—atopic dermatitis	2.69e-06	4.79e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NFKBIA—atopic dermatitis	2.68e-06	4.77e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL2—atopic dermatitis	2.67e-06	4.75e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—atopic dermatitis	2.66e-06	4.72e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MAPK8—atopic dermatitis	2.61e-06	4.65e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CXCL8—atopic dermatitis	2.55e-06	4.53e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CXCL8—atopic dermatitis	2.52e-06	4.48e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK8—atopic dermatitis	2.49e-06	4.43e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK8—atopic dermatitis	2.46e-06	4.37e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CXCL8—atopic dermatitis	2.44e-06	4.33e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL2—atopic dermatitis	2.43e-06	4.33e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CXCL8—atopic dermatitis	2.42e-06	4.31e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—atopic dermatitis	2.42e-06	4.3e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL2—atopic dermatitis	2.41e-06	4.29e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—atopic dermatitis	2.41e-06	4.28e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—atopic dermatitis	2.4e-06	4.26e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—atopic dermatitis	2.39e-06	4.26e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CXCL8—atopic dermatitis	2.36e-06	4.19e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL2—atopic dermatitis	2.33e-06	4.14e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CXCL8—atopic dermatitis	2.32e-06	4.12e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—atopic dermatitis	2.32e-06	4.12e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL2—atopic dermatitis	2.32e-06	4.12e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—atopic dermatitis	2.3e-06	4.1e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—atopic dermatitis	2.25e-06	4e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—atopic dermatitis	2.24e-06	3.98e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK8—atopic dermatitis	2.24e-06	3.98e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK8—atopic dermatitis	2.22e-06	3.94e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—atopic dermatitis	2.22e-06	3.94e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—atopic dermatitis	2.21e-06	3.92e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK8—atopic dermatitis	2.14e-06	3.81e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL8—atopic dermatitis	2.14e-06	3.8e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK8—atopic dermatitis	2.13e-06	3.79e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL8—atopic dermatitis	2.1e-06	3.74e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL8—atopic dermatitis	2.1e-06	3.73e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL8—atopic dermatitis	2.09e-06	3.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL8—atopic dermatitis	2.09e-06	3.71e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK8—atopic dermatitis	2.07e-06	3.68e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL8—atopic dermatitis	2.07e-06	3.67e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL8—atopic dermatitis	2.06e-06	3.66e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—atopic dermatitis	2.04e-06	3.63e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK8—atopic dermatitis	2.04e-06	3.63e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—atopic dermatitis	2.03e-06	3.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—atopic dermatitis	2.01e-06	3.57e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—atopic dermatitis	2.01e-06	3.57e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—atopic dermatitis	2e-06	3.56e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—atopic dermatitis	2e-06	3.56e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—atopic dermatitis	2e-06	3.55e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—atopic dermatitis	1.99e-06	3.54e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—atopic dermatitis	1.99e-06	3.54e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—atopic dermatitis	1.98e-06	3.53e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—atopic dermatitis	1.97e-06	3.51e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—atopic dermatitis	1.97e-06	3.5e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—atopic dermatitis	1.96e-06	3.49e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—atopic dermatitis	1.96e-06	3.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—atopic dermatitis	1.91e-06	3.4e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK8—atopic dermatitis	1.88e-06	3.34e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK8—atopic dermatitis	1.85e-06	3.29e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—atopic dermatitis	1.85e-06	3.29e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK8—atopic dermatitis	1.85e-06	3.28e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—atopic dermatitis	1.85e-06	3.28e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK8—atopic dermatitis	1.84e-06	3.27e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK8—atopic dermatitis	1.84e-06	3.26e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—atopic dermatitis	1.83e-06	3.26e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—atopic dermatitis	1.83e-06	3.25e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—atopic dermatitis	1.82e-06	3.24e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK8—atopic dermatitis	1.82e-06	3.23e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK8—atopic dermatitis	1.81e-06	3.22e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—atopic dermatitis	1.8e-06	3.19e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—atopic dermatitis	1.77e-06	3.14e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—atopic dermatitis	1.74e-06	3.1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK8—atopic dermatitis	1.68e-06	2.99e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—atopic dermatitis	1.67e-06	2.97e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—atopic dermatitis	1.59e-06	2.83e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—atopic dermatitis	1.57e-06	2.79e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—atopic dermatitis	1.43e-06	2.54e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—atopic dermatitis	1.42e-06	2.52e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—atopic dermatitis	1.37e-06	2.43e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—atopic dermatitis	1.36e-06	2.42e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—atopic dermatitis	1.32e-06	2.35e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—atopic dermatitis	1.3e-06	2.32e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—atopic dermatitis	1.2e-06	2.14e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—atopic dermatitis	1.18e-06	2.1e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—atopic dermatitis	1.18e-06	2.1e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—atopic dermatitis	1.18e-06	2.09e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—atopic dermatitis	1.17e-06	2.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—atopic dermatitis	1.16e-06	2.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—atopic dermatitis	1.16e-06	2.06e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—atopic dermatitis	1.08e-06	1.91e-05	CbGpPWpGaD
